Gilead Sciences Inc.

Foster City, CA, United States

Gilead Sciences Inc.

Foster City, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Gilead Sciences Inc. | Date: 2017-02-03

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.


The present invention relates to stable novel salt forms of N-(cyanomethyl)-4-(2-(4- morpholinophenylamino)pyrimidin-4-yl)benzamide that are suitable for the preparation of pharmaceutical formulations thereof, and their therapeutic use.


Patent
Gilead Sciences Inc. | Date: 2017-04-19

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein W, B, n, m, A, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3 -kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.


The present Invention relates to sodium (2R,5S,13aR)-7,9-dioxo-10 -((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1,2:4,5] pyrazino[2,1-b][1,3]oxazepin-8-olate Form I.


Patent
Gilead Sciences Inc. | Date: 2017-05-17

Provided are methods, uses, pharmaceutical regimens, pharmaceutical compositions, and kits comprising modulators of TLR7, including those of Formula (II); and pharmaceutically acceptable salts thereof, useful in treating HIV infections.


Patent
Gilead Sciences Inc. | Date: 2017-04-05

The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament. The compounds take the form (I).


Patent
Gilead Sciences Inc. | Date: 2017-04-05

Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo(1,2-f] [1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 2 position of the nucleoside sugar is substituted with halogen and carbon substitutents. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections caused by both wild type and mutant strains of HCV.


Patent
Gilead Sciences Inc. | Date: 2017-04-05

The present application provides for a compound of Formula IV,


Patent
Gilead Sciences Inc. | Date: 2017-01-04

The present application provides for a compound of Formula I,


Patent
Gilead Sciences Inc. | Date: 2017-09-20

Provided are compounds of Formula I:Flaviviridae virus infections, particularly hepatitis C infections.

Loading Gilead Sciences Inc. collaborators
Loading Gilead Sciences Inc. collaborators